Leonard E. Post Sells 1,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

CG Oncology Price Performance

NASDAQ:CGON opened at $34.59 on Friday. CG Oncology, Inc. has a 1-year low of $25.77 and a 1-year high of $50.23. The firm has a 50-day moving average of $35.78 and a two-hundred day moving average of $34.92.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million. On average, research analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current year.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors have recently added to or reduced their stakes in CGON. Amalgamated Bank boosted its holdings in CG Oncology by 107.6% during the third quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock worth $61,000 after buying an additional 840 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of CG Oncology during the 1st quarter worth $103,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CG Oncology in the 3rd quarter worth $241,000. Profund Advisors LLC acquired a new stake in shares of CG Oncology during the second quarter worth $300,000. Finally, HighVista Strategies LLC acquired a new stake in shares of CG Oncology during the third quarter worth $594,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. UBS Group initiated coverage on shares of CG Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $60.00 price target for the company. Bank of America reissued a “buy” rating and issued a $65.00 price objective on shares of CG Oncology in a research note on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a report on Friday. Roth Capital upgraded CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, CG Oncology presently has an average rating of “Buy” and a consensus target price of $63.88.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.